|Bid||8.50 x 1100|
|Ask||11.49 x 2200|
|Day's Range||9.95 - 10.76|
|52 Week Range||5.36 - 13.09|
|Beta (5Y Monthly)||0.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 30, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.63|
Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Concert will present a corporate overview at the 2020 UBS Virtual Global Healthcare Conference on May 19, 2020 at 3:00 p.m. ET.
Good morning and welcome to Concert Pharmaceuticals' first quarter 2020 investor update. Joining me this morning with prepared remarks are Roger Tung, our President and CEO; Jim Cassella, our Chief Development Officer; and Marc Becker, our CFO. As a reminder, today's discussion will include forward-looking statements about our future expectations, plans, and prospects.
Concert (CNCE) delivered earnings and revenue surprises of 5.41% and -65.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Concert will host a conference call and webcast April 30, 2020, at 8:30 a.m. ET to provide an update on the Company and discuss first quarter results.
Concert (CNCE) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Concert will report its first quarter 2020 financial results and host a conference call and webcast on April 30, 2020.
Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Concert announced the details of its pivotal Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata.
It's nice to see the Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) share price up 20% in a week. But that doesn't help...
Anyone researching Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) might want to consider the historical volatility of the...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees in 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]
Roger Tung has been the CEO of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) since 2006. First, this article will...
Concert (CNCE) delivered earnings and revenue surprises of 15.29% and -97.14%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.